🇬🇧 Medical cannabis in United Kingdom

C — specialist/product-gated. Cannabis-based products for medicinal use (CBPMs) are Schedule 2 controlled drugs that only a doctor on the GMC Specialist Register may prescribe; the NHS prescribes almost only the licensed medicines (Epidyolex, Sativex, nabilone), so most patients start with a private specialist prescription for unlicensed 'specials', including flower.

Misuse of Drugs Regulations 2001 (MoDR) reg 16A (in force 1 Nov 2018): a CBPM may be ordered and supplied only if it is (a) a special medicinal product used in accordance with a prescription of a 'specialist medical practitioner' — 'a doctor included in the register of specialist medical practitioners kept under section 34D of the Medical Act 1983 (the Specialist Register)' — or (b) an investigational medicinal product in a trial, or (c) a product with a marketing authorisation; smoking the product is prohibited. NHS: 'Cannabis-based medicine can only be prescribed on the NHS by a specialist hospital doctor, or under a specialist's supervision' and in practice covers Epidyolex, nabilone and Sativex (nhs.uk, last reviewed 27 May 2022). Unlicensed products are supplied under the MHRA 'specials' regime (guidance updated 29 Jan 2025). The private specialist layer is large and flower is available, but the legal gate is the specialist prescription, hence C rather than A.

Source: The Misuse of Drugs Regulations 2001, regulation 16A (legislation.gov.uk) · read 27 September 2026

Three cannabis medicines hold a UK marketing authorisation: Sativex (nabiximols) oromucosal spray, Epidyolex (cannabidiol) oral solution and Nabilone capsules. Everything else a patient is likely to be prescribed — dried flower, oils, capsules, pastilles — is an unlicensed "special", not a licensed medicine.

Regulation 16A of the Misuse of Drugs Regulations 2001 (inserted 1 November 2018) permits only three categories to be ordered: a "special medicinal product" prescribed by a specialist medical practitioner, an investigational medicinal product in a clinical trial, or a product with a marketing authorisation. A "special" is supplied under the exemption in regulation 167 of the Human Medicines Regulations 2012 — it has not been assessed by the MHRA for safety, quality or efficacy, is made or imported to the prescriber's specification for one named patient, and may only be supplied "in response to an unsolicited order". Licensed products, from the electronic medicines compendium (read 2026-09-06): Sativex PL 61050/0001 (SVX Therapeutics Limited, first authorised 16 June 2010); Epidyolex PLGB 36772/0001 (Jazz Pharmaceuticals Research UK Limited, first authorised 01/01/2021); Nabilone PL 25298/0157 (Brown & Burk UK Ltd, first authorised 23/01/2017). Regulation 16A(3) also prohibits self-administration by smoking: "A person shall not self-administer a cannabis-based product for medicinal use in humans by the smoking of the product" — vaporising is how flower is intended to be taken.

Source: Misuse of Drugs Regulations 2001, regulation 16A (legislation.gov.uk) · read 6 September 2026

Only a doctor on the GMC Specialist Register may start you on an unlicensed cannabis medicine. A GP cannot initiate one, and in practice almost no NHS specialist will — the prescribers are consultants working in private clinics.

Misuse of Drugs Regulations 2001 reg 16A(1)(a)(ii) requires a special CBPM to be "for use in accordance with a prescription or direction of a specialist medical practitioner", and reg 16A(6) defines that as "a doctor included in the register of specialist medical practitioners kept under section 34D of the Medical Act 1983 (the Specialist Register)". The requirement was inserted by the Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018 (SI 2018/1055), reg 4, in force 1 November 2018. It applies only to unlicensed products: licensed Sativex, Epidyolex and Nabilone can be prescribed by any practitioner otherwise authorised. NICE NG144 rec 1.5.1 adds that the specialist "should also have a special interest in the condition being treated". A GP or non-medical prescriber may issue subsequent prescriptions "under the direction of" the specialist: NG144 rec 1.5.2 allows this as a shared-care agreement only where the condition is stable and the other prescriber is confident to make a fully informed decision, and rec 1.5.3 keeps dose adjustment with the initiating specialist. CQC (guidance updated 8 July 2026) expects services to have "a minimum of 2 GMC specialist registered doctors" scrutinising and ratifying prescribing decisions, and warns against services that "delegate care entirely to non-specialists with no ongoing practical involvement from the specialist". Shared care with an NHS GP is possible in law but is a voluntary agreement no GP can be compelled to enter, and it does not make the medicine NHS-funded.

Source: Misuse of Drugs Regulations 2001, reg 16A(6) and NICE NG144 recommendations 1.5.1–1.5.3 · read 6 September 2026

A Schedule 2 controlled-drug prescription. Private ones must be written on a pink FP10PCD form issued by NHS England, must carry the prescriber's identification number, and must be dispensed within 28 days of the date on them.

Misuse of Drugs Regulations 2001 reg 15(1) requires the prescription to "be written so as to be indelible, be dated and be signed by the person issuing it with his usual signature", to name and address the patient, and to state the dose plus the total quantity "in both words and figures". Reg 15(1)(aa) requires a private prescription to be "written on a prescription form provided by NHS England or an equivalent body for the purposes of private prescribing" (the FP10PCD), and reg 15(1)(ab) requires the prescriber identification number. There is no handwriting requirement — that was removed in 2005, and Schedule 2 and 3 prescriptions have been able to travel by EPS with an advanced electronic signature since July 2015 — but private CBPM prescriptions are in practice paper FP10PCD forms, which NHSBSA describes as "often handwritten". Validity: reg 16(1)(e) bars supply "later than twenty-eight days after the appropriate date". Quantity: there is no statutory maximum; DHSC strongly recommends limiting Schedule 2, 3 and 4 CDs to 30 days' treatment, and a pharmacist may lawfully dispense more. At collection, reg 16(6) requires the pharmacist to establish who is collecting a Schedule 2 drug and permits them to request identity evidence and refuse supply — so bring photo ID. Pharmacies must send original FP10PCD forms to NHSBSA "no later than the fifth day of the month following which they were supplied", which is why national private-prescription counts exist at all.

Source: Misuse of Drugs Regulations 2001, regs 15 and 16 (legislation.gov.uk) · read 6 September 2026

Yes — a specialist may lawfully assess you and start an unlicensed cannabis prescription by video, and most UK clinics work this way. Nothing in the controlled-drug rules requires a face-to-face appointment.

Neither the Misuse of Drugs Regulations 2001 nor the Human Medicines Regulations 2012 impose a face-to-face requirement for Schedule 2 prescribing; the only statutory gate is that a Specialist Register doctor directs the prescription. The constraint is regulatory rather than legal. A provider must be registered with CQC for the regulated activity "Treatment of disease, disorder or injury", and CQC states: "If you make a change to your existing service, such as offering cannabis-based products for medicinal use (CBPMs), or if you intend to prescribe these medicines remotely through an online consultation, you must update your statement of purpose and notify us in writing within 28 days of the change." On remote prescribing specifically CQC says: "If we cannot be assured that the arrangements promote safe prescribing or we have evidence that remote consultations are not being carried out safely, we may take regulatory action. For example, we could impose conditions on your registration to prevent you from prescribing cannabis-based medicinal products remotely." Some independent doctors are exempt from CQC registration, so the absence of a CQC entry is not automatically a red flag — but for a clinic offering ongoing prescribing it usually is. CQC guidance page last updated 8 July 2026.

Source: CQC — Cannabis-based medicinal products: remote online prescribing (last updated 8 July 2026) · read 6 September 2026

You cannot take the prescription to your local high-street chemist. Unlicensed cannabis medicines are dispensed by a small number of specialist pharmacies that work with licensed importers, and the medicine is usually posted to you.

Three things exclude ordinary community pharmacies. First, regulation 167 of the Human Medicines Regulations 2012 allows a "special" to be supplied only "in response to an unsolicited order" and "for use by a patient for whose treatment that person is directly responsible" — a pharmacy cannot simply stock it as a line. Second, nearly all UK CBPMs are imported: MHRA guidance requires the importer to hold a Manufacturer's (Specials) Licence or a Wholesale Dealer's Licence WDA(H), to hold Home Office controlled-drug import and possession licences, and to notify MHRA at least 28 days before each import, with a limit of 25 individual doses or treatment courses per notification and MHRA able to object within that window. Third, the resulting supply chain is deliberately narrow, so the pharmacies that dispense CBPMs are a handful of specialist dispensers tied to the clinics and importers rather than a network you can walk into. Regulation 167(2) does permit supply "for use under the supervision of a pharmacist in a registered pharmacy", so a high-street pharmacy is not barred in law — it simply has no practical route to source the product for you in the 28 days your prescription stays valid. Expect the clinic to nominate its own pharmacy and deliver by tracked courier.

Source: MHRA — The supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use in humans ('specials') · read 6 September 2026

Effectively none. NHSBSA confirmed in 2026 that fewer than five individuals in total have been prescribed an unlicensed cannabis-based product on the NHS in the community in England between 1 November 2018 and 31 December 2025. Assume you will pay for everything yourself.

Two numbers are routinely confused and must be kept apart. (1) UNLICENSED CBPMs on the NHS: NHSBSA FOI-03595 was asked for the number of individuals prescribed CBPMs on the NHS between 1 November 2018 and 31 December 2025 and replied: "We can confirm that we do hold the requested information However, I have decided not to release the exact number of individuals as the number is fewer than five." NHSBSA FOI-02725 (May 2025) separately stated that "the monthly number of NHS unlicensed and private licensed medical cannabis patients is less than five". So the widely repeated "only a handful of NHS prescriptions ever" is correct and officially sourced. (2) LICENSED cannabis medicines on the NHS, which are a genuinely used but small NHS treatment: a Written Answer of 26 March 2025 (UIN 40028) gave 5,413 items prescribed to 880 identified patients in England for Epidyolex, nabilone and Sativex between February 2024 and January 2025. Guidance: NICE NG144 (published 11 November 2019, last updated 22 March 2021) recommends nabilone as an add-on for chemotherapy-induced nausea and vomiting; a 4-week trial of THC:CBD spray for moderate-to-severe MS spasticity subject to the pay-for-responders scheme; and cannabidiol via technology appraisals TA614/TA615 (Dravet, Lennox–Gastaut) and TA873 (tuberous sclerosis complex). For chronic pain NG144 rec 1.2.1 says: "Do not offer the following to manage chronic pain in adults: nabilone, dronabinol, THC (delta-9-tetrahydrocannabinol), a combination of cannabidiol (CBD) with THC." NG144 makes no positive recommendation for unlicensed CBPMs in any indication, which is the practical reason NHS funding does not follow.

Source: NHSBSA FOI-03595 — individuals prescribed CBPMs on the NHS, 1 Nov 2018 to 31 Dec 2025 (published March 2026) · read 6 September 2026

Budget for two separate costs: clinic fees, which are now low and publicly advertised (roughly £5–£50 per month or £29–£49 per appointment at the large clinics), and the medicine itself, which is the real expense and which most clinics will not quote you until you are a patient.

Published clinic fees, all read on 2026-09-06 on the seller's own page: Curaleaf Clinic — £30 per appointment pay-as-you-go, or £5 per month, or £50 per year (curaleafclinic.com/pricing), and the page states "This pricing does not include the cost of your medicine, as this will vary per person depending on what is prescribed." Alternaleaf — £29 per appointment or £5 per month membership (alternaleaf.co.uk/pricing). Mamedica — onboarding £49 (Flex) to £200 (Access), plus £9.99 per delivery and £10 per travel letter, and states "The cost of your medication is not included" (mamedica.co.uk/pricing). Releaf — consultation £29.99 (advertised as reduced from £99.99) and a Releaf+ plan at £39.99 per month (releaf.co.uk/pricing). Published medicine prices are rare, because regulation 167(3) HMR 2012 and regulation 279 HMR 2012 prohibit advertising unlicensed medicines. Two clinics do publish an entry price on their own public pages: Alternaleaf states flower "starts from £5 per gram", and Releaf states "Get medical cannabis from £7.99 per gram" and 30ml of oil for £134.99. These are floor prices for the cheapest product on a subscription tier, not a typical price, and no clinic publishes a full price list publicly. We do not publish a per-gram range beyond these two figures because no seller publishes an upper bound we could source. A rough scale of the medicine cost: at a 30g/month prescription, which Releaf uses as its own worked example, £5–£8 per gram is £150–£240 per month before any higher-priced cultivar.

Source: Curaleaf Clinic pricing page (read 6 September 2026) · read 6 September 2026

There is a 2 microgramme per litre THC blood limit that any regular patient will exceed, but section 5A(3) of the Road Traffic Act 1988 gives you a statutory medical defence if the drug was prescribed to you and you took it exactly as directed. You can still be arrested and charged first, and the defence is no protection at all if your driving is actually impaired.

The offence is section 5A Road Traffic Act 1988; the limit for delta-9-tetrahydrocannabinol is 2 microgrammes per litre of blood, set by the Drug Driving (Specified Limits) (England and Wales) Regulations 2014 (SI 2014/2868) and, for Scotland, the Drug Driving (Specified Limits) (Scotland) Regulations 2019 (SSI 2019/83, in force 21 October 2019, identical limit). The defence, section 5A(3), verbatim: "It is a defence for a person (‘D’) charged with an offence under this section to show that—(a) the specified controlled drug had been prescribed or supplied to D for medical or dental purposes, (b) D took the drug in accordance with any directions given by the person by whom the drug was prescribed or supplied, and with any accompanying instructions (so far as consistent with any such directions) given by the manufacturer or distributor of the drug, and (c) D's possession of the drug immediately before taking it was not unlawful under section 5(1) of the Misuse of Drugs Act 1971." Section 5A(4): "The defence in subsection (3) is not available if D's actions were—(a) contrary to any advice, given by the person by whom the drug was prescribed or supplied, about the amount of time that should elapse between taking the drug and driving a motor vehicle, or (b) contrary to any accompanying instructions about that matter." Section 5A(5) puts the burden on the Crown once the defence is raised: "If evidence is adduced that is sufficient to raise an issue with respect to the defence in subsection (3), the court must assume that the defence is satisfied unless the prosecution proves beyond reasonable doubt that it is not." Three practical consequences. First, keep the prescription, the dispensing label and any written timing advice with you — the defence turns on proving prescription and compliance. Second, ask your specialist to put any wait-before-driving interval in writing and follow it exactly; breaching it destroys the defence outright under 5A(4). Third, the defence covers only the section 5A limit offence. CPS legal guidance directs prosecutors to consider section 4 RTA 1988 (driving while unfit through drink or drugs) as an alternative charge — there is no medical defence to impairment. Note also that section 5A does not extend to Northern Ireland: gov.uk states "The law does not cover Northern Ireland but you could still be arrested if you're unfit to drive." Beware gov.uk's plain-English drug-driving page, which lists the medicines you may drive on and does not mention THC; that omission does not remove the statutory defence, which applies to any specified controlled drug lawfully prescribed.

Source: Road Traffic Act 1988, section 5A (legislation.gov.uk) · read 6 September 2026

To leave the UK you do not need a Home Office licence — you need to be able to prove the medicine is yours and, far more importantly, to check that the destination country allows it at all, because a UK prescription gives you no rights abroad. Coming into the UK, non-residents may carry up to a 3-month supply of a lawfully prescribed Schedule 2–4 medicine with a doctor's letter.

Leaving the UK, current Home Office guidance (published 16 August 2019, last updated 11 April 2023) says only: "If you're leaving the UK with medicine that contains a controlled drug you should be able to prove it's yours with either a prescription or letter from your clinician", followed by the warning that "You could get a fine or go to prison if you travel with medicine that is illegal in another country. Check with the embassy of the country you're going to before you travel." There is no outbound personal-licence scheme in the current guidance; clinics sell "travel letters" (Mamedica £10) but these are a convenience document, not a licence, and carry no weight with a foreign border force. Entering the UK, the personal import policy covers "up to a 3-month supply of any schedule 2-4 (part I) drugs in the form of a medicinal product which have been lawfully prescribed to you in your country of habitual residence", with medicines "carried on your person" and a clinician letter giving your name, the medicines with doses, strength and frequency, and the prescriber's signature and professional registration details; the quantity carried must be visibly no more than three months' worth given your travel dates. Cannabis flower and oils prescribed abroad are Schedule 2 in the UK and fall within this policy. Two traps: a UK resident prescribed controlled drugs abroad is NOT covered by the personal import policy and must email dflu.ie@homeoffice.gov.uk before returning; and "Medicines containing controlled drugs cannot be posted to you from overseas" — anything mailed in will be seized. All medicine containing a controlled drug "must be carried with you in your hand luggage when entering or leaving the UK". Practically, at a UK airport the interaction is with Border Force, and the thing that ends it quickly is a dispensing-labelled package matching a paper prescription or clinician letter in your hand luggage.

Source: Home Office — Travelling with medicine containing controlled drugs (last updated 11 April 2023) · read 6 September 2026

A visitor can be seen and prescribed privately by a UK Specialist-Register doctor — the law has no residency test — but a prescription from any other country cannot be dispensed in the UK because CBPMs are Schedule 2 controlled drugs. You may bring up to three months' supply of your own prescribed cannabis medicine with a prescriber's letter; more than that needs a Home Office personal licence.

1. Non-residents: MoDR 2001 reg 16A conditions supply only on a Specialist-Register prescription; no residency, NHS-number or nationality condition exists for a private prescription (NHS treatment is separately subject to NHS eligibility). No official page addresses non-resident cannabis patients ('not published'). 2. Foreign prescriptions: Human Medicines Regulations 2012 reg 214(6): 'An approved country health professional is an appropriate practitioner in relation to any prescription only medicine other than a product subject to special medical prescription', and reg 213(3): 'any substance or product for the time being specified in Schedule 1, 2 or 3 to the Misuse of Drugs Regulations 2001 … is designated as a product subject to special medical prescription'. CBPMs are Schedule 2, so an EEA/Swiss (or any foreign) cannabis prescription is not dispensable in the UK; prescriptions from outside the approved-country list are not recognised for any POM. 3. Bringing medicine in: GOV.UK — 'You can only bring up to 3 months supply of your medicine'; 'up to a 3-month supply of any schedule 2-4 (part I) drugs in the form of a medicinal product which have been lawfully prescribed to you in your country of habitual residence' may be carried without a licence, in hand luggage, with a letter giving your name, travel dates, the medicines with quantities, doses and strength, and the prescriber's signature and registration details; longer stays/quantities need a personal import/export licence from the Home Office Drugs and Firearms Licensing Unit (apply about a month ahead); 'You cannot bring schedule 1 drugs into the UK without a licence' — cannabis that is not a CBPM (e.g. product not prescribed as a medicine) is Schedule 1. The UK is outside Schengen, so the Article 75 certificate is not the UK instrument (a letter is), though carrying one does no harm. 4. Foreign telemedicine prescription: not dispensable (see 2); UK online/video consultations with a Specialist-Register doctor are lawful and are how most private prescriptions are issued.

Source: The Human Medicines Regulations 2012, regulation 214 (appropriate practitioners; approved country health professionals) — legislation.gov.uk · read 27 September 2026

Nothing pending was found. The GOV.UK medicinal-cannabis collection (last updated 15 July 2026) lists no new legislation, and the 2001 Regulations as revised to September 2026 leave regulation 16A unchanged since 2018.

GOV.UK collection 'Medicinal cannabis: information and resources' (updated 15 July 2026) contains the 2018 rescheduling documents plus the 29 Jan 2025 guidance 'Supply unlicensed medicinal products (specials)' and nothing announcing a legal change. On legislation.gov.uk the MoDR 2001 text is revised to 19 Sept 2026: reg 15 (prescription requirements for Schedule 2/3 drugs) carries amendments through 2025 but reg 16A (CBPMs) still shows the 1 Nov 2018 version. NHS England's page states the government 'has no intention of legalising the use of cannabis for recreational (non-medical) use'. No consultation on CBPM prescribing, telemedicine or scheduling was found on the official pages opened.

Source: GOV.UK — Medicinal cannabis: information and resources (collection) · read 27 September 2026

No official count of UK medical cannabis patients exists. The government counts prescription items, not people: 282,920 private unlicensed CBPM items were dispensed in England in 2023, 659,293 in 2024 and 1,701,064 in 2025. The most careful public estimate of actual patients is 60,000–75,000 active patients, and it is an industry-derived estimate, not a statistic.

Why there is no official number: NHSBSA processes private controlled-drug prescriptions because reg 15(1)(aa) forces them onto FP10PCD forms, but it captures items, not patient identifiers, for private prescribing. Asked directly for private patient counts it has said it does not hold them, and for NHS unlicensed patients it suppresses the figure because it is fewer than five. The item counts are official and downloadable: NHSBSA FOI-03401 (published 22 December 2025) gives 282,920 items in 2023 and 659,293 in 2024; NHSBSA FOI-03941 (published 30 July 2026) breaks 2025 down by product and month, summing to 1,701,064 items, rising through the year from 92,136 in January to 195,410 in October. "Items" counts appearances of a product on a form, so one patient on three products for twelve months can generate 36 items — the item series measures market growth, not headcount. The best-sourced patient estimate is 60,000–75,000 active UK patients as of mid-2026, produced by Plantz and Cannavec.ai and published via the Cannabis Industry Council on 15 May 2026; its stated method combines NHSBSA dispensing data with "industry and clinician estimates from organisations including the Medical Cannabis Clinicians Society, the Cannabis Industry Council, Prohibition Partners, and Cannamonitor", and it deliberately uses a range "to reflect the limitations of the available data and avoid overstating precision". This is a trade-sector estimate and we label it as one. Higher figures circulating in the trade press (e.g. "140,000 patients in 2026") come from commercial market reports and we do not repeat them.

Source: NHSBSA FOI-03401 — private unlicensed cannabis items dispensed in England, 2023 and 2024 (published 22 December 2025) · read 6 September 2026